To understand Key Opinion Leaders perspectives around the accessibility and acceptability of emerging treatment options along with GLP-1 agonists unmet need of current therapies Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies development and launch strategy.
YX: Project administration, Resources, Supervision, Validation, Writing review and editing
Never adjust dosing without consulting your healthcare provider, as individualized titration balances efficacy with tolerability
In some cases, people report new breakouts or worsening acne, which can feel unexpected
In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study (64) despite comparable putative GLP-1R occupancy at these doses (47)